An interventional study of anthropometric measurement in Diffuse Large B Cell Lymphoma and Grade IIIB Follicular Lymphoma, sponsored by Centre Henri Becquerel. Completed at 1 site in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2016-10-05.
Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Diagnostic
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
1,432 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 98 is above the median of 47 across 1,214 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Centre Henri Becquerel is the lead sponsor of 59 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months * anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment) * albuminemia, transthyretin, orosomucoid, CRP * functional test to attest the muscular strength: hand grip test, unipodal test, up and go test * hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2 * OS and PFS at 18 and 24 months * GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis
Procedure: anthropometric measurement
To attest the muscular strength: hand grip test, balance test, up and go test
Also known as: Hand Grip strength test, Timed get up and go test
progression free survival
Time frame: at 18 months
progression free survival
Time frame: at 24 months
rate of over grade 2 toxicities
Time frame: at the first and second courses of chemotherapy (day 21 and day 42)
determination of both molecular subtypes GCB and ABC
according DASL technology (c-DNA mediated annealing selection extension and ligation)
Time frame: at 24 months
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2012, a primary completion of Dec 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Centre Henri Becquerel